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The cost of definitive therapy was compared in 
25 patients who underwent radiofrequency cath- 
eter ablation of accessory pathways in 1990 and 
25 patients who underwent surgical ablation of 
accessory pathways in 1989. In the radiofre- 
quency group, 23 of 25 patients had a single ac- 
cessory pathway and the remaining 2 patients 
each had 2 accessory pathways. In the surgical 
group, 20 patients had a single accessory path- 
way and S patients each had 2 accessory path- 
ways. The success rate was 96% in each group. 
The mean duration of hospitalization was 3 f 1 
days in the radiofrequency group and 9 f 4 days 
in the surgical group (p <O.OOOl). All the cost 
data are expressed in fiscal year 1990/1991 
dollar values. The total cost of therapy in the ra- 
diofrequency group was $14,919 f $6,740 
compared with $53,265 f $12,755 in the surgi- 
cal group (p <O.OOOl). The cost of radiofrequen- 
cy ablation consisted of a hospital charge of 
$7,753 f $3,472 and physician fees of $7,166 
f $3,439. The hospital charge included charges 
for use of the electrophysiology laboratory, hos- 
pital stay, electrocardiograms, echocardiograms 
and blood studies. The cost of surgery consisted 
cf a hospital charge of $37,706 f $10,179 and 
physician fees of $15,557 f $3,149. The hospi- 
tal charge in the surgical group included the 
costs of a baseline electrophysiology study, in- 
hospital care and a follow-up office visit. In con- 
clusion, radiofrequency catheter ablation of ac- 
cessory pathways results in a dramatic reduction 
in the cost of definitive therapy in patients with 
the Wolff-Parkinson-White syndrome. 
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R 
adiofrequency catheter ablation has been 
shown to be a safe and efficacious means of 
interrupting accessory pathway conduction. 1,2 
This treatment method has a high degree of patient 
acceptance because it eliminates the need for open- 
chest surgery. An important additional advantage of 
this therapy is the anticipated cost-savings associated 
with its use, but few data on this aspect have been pub- 
lished to date. Therefore, this study describes the cost 
of accessory pathway ablation using radiofrequency 
current and compares this cost with that of a standard 
surgical approach. 3 
METHODS 
This was a retrospective study of 25 consecutive pa- 
tients who underwent surgical ablation of accessory 
pathways in 1989 and 25 consecutive patients who un- 
derwent radiofrequency ablation of accessory pathways 
in 1990. All the patients in the study were referred 
to the University of Michigan Medical Center for 
management of recurrent supraventricular tachyarr- 
hythmias. 
Electrophysiologic study: All patients underwent a 
diagnostic electrophysiologic test at least 5 half-lives af- 
ter discontinuation of all antiarrhythmic drugs and af- 
ter providing informed consent. Three 6Fr quadripolar 
catheters were inserted into a femoral vein and posi- 
tioned at the high right atrium, across the tricuspid 
valve to record the His bundle electrogram and against 
the right ventricular apex or septum. An additional 
quadripolar catheter was inserted into the subclavian or 
internal jugular vein and positioned in the coronary si- 
nus. After the catheters were in place, 3,000 U of hepa- 
rin were administered intravenously. Programmed atri- 
al and ventricular stimulation was performed using a 
Bloom DTU 201 stimulator (Bloom Associates, Nar- 
beth, Pennsylvania). Standard techniques were used to 
elucidate the presence of an accessory pathway and to 
confirm its participation as a critical limb of the tachy- 
cardia circuit.4 A Siemens-Elema Mingograf 7 ink-jet 
recorder provided both a continuous oscilloscopic dis- 
play and a permanent record of leads Vi, I and III and 
the intracardiac electrograms. 
Radiofrequency ablation group: The group com- 
prised 11 men and 14 women (mean age 40 f 16 
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years, range 14 to 74). Mean duration of symptoms 
was 21 f 17 years (range of 1 month to 60 years). 
They had been treated with a mean of 2 f 1 antiar- 
rhythmic drugs before undergoing radiofrequency abla- 
tion and most of these drugs had been poorly tolerated 
or were ineffective. Twenty-three of the 25 patients had 
a single accessory pathway and the remaining 2 pa- 
tients each had 2 accessory pathways. Fifteen of the 
accessory pathways were left-sided, 9 were septal and 3 
were right-sided; 17 displayed manifest preexcitation 
and 10 were concealed. 
On completion of the diagnostic portion of the elec- 
trophysiologic study, radiofrequency catheter ablation 
was attempted during the same session. The ablation 
protocol was approved by the Human Research Com- 
mittee at the University of Michigan and all patients 
provided written informed consent before undergoing 
the procedure. Radiofrequency ablation was performed 
using a 7Fr quadripolar deflectable tip catheter with a 
4 mm distal electrode and 5 mm interelectrode spacing 
(Mansfield, Watertown, Massachusetts). For left-sided 
accessory pathways, the catheter was advanced from 
the femoral artery to the left ventricle and positioned in 
the atrioventricular sulcus under the mitral valve anu- 
lus. For right-sided accessory pathways, the catheter 
was advanced from the inferior cava to the right atrium 
at the level of the tricuspid valve. For septal accessory 
pathways, the ablation catheter was advanced from the 
superior or inferior vena cava to the coronary sinus OS 
or the anterior atrial septum. A detailed description of 
the mapping and ablation technique has been previous- 
ly provided.2 
On completion of the radiofrequency ablation proce- 
dure, the patients were admitted to a telemetry unit for 
48 hours of monitoring. Three serial blood samples 
were obtained at 8-hour intervals for determination of 
the plasma concentrations of creatine kinase and its 
MB subfraction. A daily 1Zlead electrocardiogram 
was recorded and cross-sectional echocardiography and 
Doppler study were performed within 24 hours of the 
radiofrequency ablation. In patients in whom the acces- 
sory pathway was concealed, a brief electrophysiologic 
test was performed after 48 hours to confirm successful 
ablation. In patients in whom the accessory pathway 
was manifest, the absence of delta waves on the 48- 
hour electrocardiogram was regarded as evidence of a 
successful outcome and a repeat electrophysiologic 
study was not performed before discharge from the 
hospital. All patients underwent a final electrophysio- 
logic test after 3 months on an outpatient basis to assess 
the long-term efficacy of the procedure. 
Surgkal group: This group comprised 14 men and 
11 women (mean age 30 f 11 years, range 13 to 60). 
The mean duration of symptoms was 11 f 11 years 
(range 1 month to 40 years). The patients had been 
treated with 2 f 2 antiarrhythmic drugs before under- 
going surgery. These drugs had been ineffective or asso- 
ciated with unacceptable side effects for almost all of 
the patients. Twenty of the 25 patients had a single 
accessory pathway and the remaining 5 patients each 
had 2 accessory pathways. Twenty of the accessory 
pathways were left-sided, 8 were septal and 2 were 
right-sided; 20 displayed manifest preexcitation and 10 
were concealed. 
Surgical ablation was performed using an endocar- 
dial approach.3 After the induction of general anesthe- 
sia, the chest was opened through a median sternotomy 
incision. The accessory pathway(s) was localized using 
standard mapping techniques4 and the patient was then 
placed on cardiopulmonary bypass. When the surgical 
ablation was completed the patient was weaned from 
cardiopulmonary bypass and intraoperative epicardial 
mapping was repeated to evaluate the efficacy of the 
surgical dissection. Before discharge from the hospital, 
bedside pacing using temporary epicardial pacing leads 
was performed to confirm a successful surgical result. 
Cost analysis: Retrospective review of each patient’s 
clinical record was performed to determine the number, 
duration and dates of hospital admissions and the num- 
ber and dates of office visits that were related directly 
to the ablation procedure. Only charges billed from the 
University of Michigan Medical Center were included 
in the present analysis. The costs incurred by each pa- 
tient were divided into hospital and physician charges. 
Itemized bills were obtained from the patients’ accounts 
oftice for all ablation-related admissions and office vis- 
its. The hospital costs include the charges for room and 
board, operating room or electrophysiology laboratory 
charges, and charges for nursing and ancillary care, 
drugs, blood tests, x-rays, electrocardiograms and echo- 
cardiograms. The analysis incorporated the cost of a l- 
month follow-up oflice visit and an electrocardiogram 
at rest for all patients. All patients treated surgically 
had a chest x-ray during the follow-up oflice visit and 
this cost was also included. 
Physician charges for all ablation-related hospital 
admissions and oflice visits were obtained from the rel- 
evant physician-associates groups at the University of 
Michigan Medical Center. The cost of the 3-month fol- 
low-up electrophysiologic study in the radiofrequency 
ablation group was excluded from the present analysis 
because the indication for this study was based on the 
investigational nature of the procedure and the need to 
document accurately its long-term effects. As radiofre- 
quency ablation becomes established in clinical prac- 
tice, this follow-up study will not be necessary. 
To conduct a valid comparison and to provide cost 
data that are meaningful in 1991, an adjustment was 
made to convert all costs to their 1990/1991 fiscal year 
dollar values. The annual increase in hospital charges 
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r TABLE I Age, Number of Accessory Pathways, Duration of Hospital Stay and Individual Costs in 25 Patients Undergoing Surgical 
Ablation 
Pt. No. Age (yr) No. of APs 
1 38 1 
2 23 1 
3 42 1 
4 60 1 
5 39 1 
6 15 1 
7 28 1 
8 28 2 
9 28 1 
10 29 2 
11 30 2 
12 47 1 
13 23 1 
14 28 1 
15 22 
16 15 i 
17 41 2 
18 33 1 
19 22 1 
20 20 2 
21 41 1 
22 36 1 
23 17 1 
24 23 1 
25 13 1 
Mean k SD 30-c 11 
APs = accessory pathways; SO = standard deviation. 
Hospital Hospital Physician Total 
Stay (days) Charges ($1 Charges ($) Charges ($) 
10 35,437 16,280 51,717 
6 30,815 14,585 45,400 
7 28,668 15,308 43,976 
8 34,977 16,898 51,875 
8 33,931 10,937 44,868 
8 33,470 15,945 49,415 
13 41,163 17,586 58,749 
11 36,053 15,774 51,827 
8 32,441 15,616 48,057 
10 45,218 15,633 60,851 
6 33,590 14,574 48,164 
10 46,893 17,647 64,540 
6 33,781 14,681 48,462 
15 36,068 10,319 46,387 
6 30,031 15,286 45,317 
7 28,945 15,178 44,123 
11 62,111 22,625 84,736 
8 38,324 14,443 52,767 
10 33,839 13,931 47,770 
24 72,636 24,892 97,528 
11 35,659 9,832 45,491 
8 40,844 15,099 55,943 
12 37,203 15,685 52,888 
7 28,892 14,477 43,369 
8 31,714 15,700 47,414 
9k4 37,708 AI 10,179 15,557 + 3,149 53,265 k 12,755 
and physician fees was obtained from the University of 
Michigan Medical Center budget and medical service 
plan offices, respectively. The annual increase in hospi- 
tal charges was 7.4% for fiscal year 1989/ 1990 and 
13.1% for fiscal year 1990/1991. The annual increase 
in physician fees was 7.36% for fBca1 year 1989/1990 
and 5.7% for fiscal year 1990/ 199 1. The annual physi- 
cian fee increase is based on the Physicians Services 
Index of the Consumer Price Index using the 3-month 
period of February through April. The dollar values 
presented in this study represent the mean total of what 
was billed to each patient for either radiofrequency or 
surgical ablation. The cost to charge ratio expresses the 
actual cost of delivering a service as a proportion of 
what is billed to the patient for providing that service. 
In the present study, the cost-to-charge ratio for hospi- 
tal services was 0.56 in the radiofrequency group and 
0.61 in the surgical group. Cost-to-charge ratios are not 
available for professional fees. 
Statistical analysis: The costs of radiofrequency and 
surgical ablation were compared using the unpaired t 
test. A p value <0.05 was considered significant and all 
numerical data are expressed as mean f standard devi- 
ation. 
RESULTS 
Patient characteristics: The patients in the radiofre- 
quency group were significantly older than the patients 
in the surgical group (40 f 16 vs 30 f 11 years; p 
Cost data (Tables I and II): The mean total cost of 
definitive therapy in the radiofrequency group was 
$14,919 f $6,740 compared with $53,265 f $12,755 
in the surgical group (p <O.OOOl). Analysis of the 
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<O.Ol). The duration of arrhythmia symptoms before 
ablation was significantly longer in the radiofrequency 
group than in the surgical group (2 1 f 17 vs 11 f 11 
years; p <O.OS). There was no significant difference in 
the mean number of antiarrhythmic drugs used to treat 
patients before they underwent ablation (1.9 f 1.4 in 
the radiofrequency group versus 2.4 f 1.6 in the surgi- 
cal group). 
Efficacy of ablation: Radiofrequency ablation was 
achieved successfully in 22 of 25 patients (88%) during 
a single hospital admission and in 2 of 25 patients (8%) 
during 2 hospital admissions. Surgery was successful 
for 24 of 25 patients (96%) and 21 of 25 patients had a 
single hospital admission. Among the 4 patients who 
had >l hospital admission, 3 patients required 2 hospi- 
tal admissions and 1 patient had 3 hospital admissions. 
This latter patient (no. 12, Table I) was referred for 
management of refractory supraventricular tachycardia 
and had a l-day hospital admission for a baseline elec- 
trophysiologic study and stabilization on a medical regi- 
men pending surgery. He had a 7-day admission for 
surgical ablation of a concealed left-sided accessory 
pathway and a 2-day readmission 9 days after dis- 
charge from the hospital for management of atria1 fi- 
brillation. 
r 
TABLE II Age, Number of Accessory Pathways, Duration of Hospital Stay and Individual Costs in 25 Patients Undergoing 
Radiofrequency Ablation 
Pt. No. Age (yr) No. of APs 
1 25 1 
2 31 1 
3 38 1 
4 50 1 
5 31 1 
6 40 1 
7 35 1 
8 14 2 
9 50 1 
10 24 1 
11 42 1 
12 57 1 
13 32 1 
14 42 1 
15 29 1 
16 54 1 
17 37 1 
18 16 1 
19 63 1 
20 60 2 
21 67 1 
22 34 1 
23 16 1 
24 74 1 
25 52 1 
Mean f SD 40% 16 
















































































































14,919 f 6,740 
component charges in each group revealed that the 
mean hospital charge per patient in the radiofrequency 
group was $7,753 f $3,472 compared with $37,708 f 
$10,179 in the surgical group (p <O.OOOl). The mean 
physician charge per patient in the radiofrequency 
group was $7,166 f $3,439 compared with $15,557 f 
$3,149 in the surgical group (p <O.OOOl). In the radio- 
frequency group, the physician charge consisted almost 
entirely of the electrophysiologist’s fee. In the surgical 
group, the total physician charge included professional 
fees billed from electrophysiology, cardiothoracic sur- 
gery, anesthesiology and radiology. Although both the 
hospital and physician charges were significantly lower 
in the radiofrequency group than in the surgical group, 
the greater relative reduction occurred in the hospital 
costs. Figure 1 shows the direct relation between the 
duration of hospital stay and the total cost of definitive 
therapy in the radiofrequency and surgical ablation 
groups. Regression analysis revealed an R-squared val- 
ue of 0.78 (p <O.OOOl). 
Mean number of days spent in the hospital to 
achieve accessory pathway ablation was 3.1 f 1.3 in 
3 80,000 




auesmry pathways. Rewedam analytis 
(b 40,000 
revealed an R-sqmred value of 0.78 (p 5 
<0.ooo1). + 20,000 A Surgical ablation patients 
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the radiofrequency group compared with 9.5 f 3.8 in 
the surgical group (p <O.OOOl). Mean number of hos- 
pitalizations deemed related to accessory pathway abla- 
tion was 1.1 f 0.3 in the radiofrequency group and 1.2 
f 0.5 in the surgical group (difference not significant). 
The mean time lost from work was 11 f 19 days in the 
radiofrequency group (n = 18) and 55 f 26 in the sur- 
gical group (n = 19) (p <O.OOOl). 
Patient 20 in the surgical group had the longest ad- 
mission (24 days) and the highest charges of any pa- 
tient in the study, with hospital costs of $72,636 and 
physician fees of $24,892. He was a 20-year-old white 
man with 2 accessory pathways (left posterolateral and 
posteroseptal, both manifest). After a baseline electro- 
physiologic test, he underwent apparently successful ac- 
cessory pathway ablation. However, within hours, the 
delta waves reappeared on the 12-lead electrocardio- 
gram and he was brought back to the operating room 
for a second attempt at surgical ablation. At a follow- 
up epicardial wire pacing study 1 week later, he was 
found to have persistent conduction over his posterosep- 
tal accessory pathway and he was treated with flecai- 
nide. His postoperative recovery was prolonged due to 
persistent fevers. 
Cost data in uncomplicated cases: Because some of 
the patients, particularly in the surgical group, had a 
more complicated course than others, a cost analysis 
was performed on a subset of 10 patients in each group 
who had a rapid and uncomplicated postprocedure re- 
covery (patients 5, 8, 11, 13, 15, 16, 19, 22, 24 and 25 
in the surgical group, and patients 1, 5, 9, 10, 11, 15, 
16, 18, 22 and 25 in the radiofrequency group, Tables I 
and II, respectively). Total, hospital and physician 
charges in this subset of patients undergoing uncompli- 
cated radiofrequency and surgical ablation, respective- 
ly, were $11,012 f $2,886 vs $47,726 f $3,817 (p 
<O.OOOl), $5,281 f $1,266 vs $33,162 f $3,604 (p 
<O.OOOl) and $5,731 f $1,872 vs $14,564 f $1,395 
(p <O.OOOl). 
DISCUSSION 
The main finding of this study is that catheter-me- 
diated radiofrequency ablation accomplishes accessory 
pathway interruption at a fraction of the cost of surgi- 
cal ablation. This dramatic reduction in cost is due both 
to a reduction in hospital costs and physician charges. 
In the present study, the total cost of therapy in the 
radiofrequency group was just 28%, hospital costs were 
21% and physician fees were 46% of those in the surgi- 
cal group. Although the most significant factor result- 
ing in lower hospital costs in the radiofrequency group 
was the shorter hospital stay, other important proce- 
dure-related factors included the lack of need for oper- 
ating room facilities, care in the intensive therapy unit 
or paramedical ancillary services such as physical ther- 
apy and respiratory care. An additional cost-limiting 
feature of radiofrequency energy is that accessory path- 
way ablation was achieved during the diagnostic elec- 
trophysiologic study in most patients. The lower physi- 
cian charges in patients undergoing radiofrequency ab- 
lation reflect the absence of surgical, anesthesiology and 
radiology professional fees. When the cost analysis was 
repeated on a subgroup of patients with uncomplicated 
procedures, there was still a highly significant differ- 
ence between the cost of radiofrequency and surgical 
ablation. Also, the cost-to-charge ratio for hospital ser- 
vices was similar in the 2 groups. 
Reduced duration of hospitalization: An important 
finding of the present study is that radiofrequency abla- 
tion results in a marked curtailment in hospital stay. 
Thus, mean duration of hospital admission was 3 days 
in the radiofrequency group compared with 9 days in 
the surgical group. Almost all the patients in the radio- 
frequency group were walking without difficulty within 
12 hours of the procedure, and the only reason for con- 
tinuing their hospitalization was because of the investi- 
gational nature of the procedure. All but 1 of the pa- 
tients in the radiofrequency group had a very benign 
post procedure course and could have been discharged 
from the hospital within 24 hours. Indeed, it is our cur- 
rent practice to discharge patients without complica- 
tions from the hospital the day after undergoing radio- 
frequency ablation. In the future, it may even be feasi- 
ble to perform radiofrequency ablation of accessory 
pathways on an out-patient basis in selected patients. 
General features of radiofrequency ablation that 
promote cost-containment: There are a number of oth- 
er general reasons why radiofrequency ablation is asso- 
ciated with cost-containment. The recent dramatic es- 
calation in medical care costs has been attributed, in no 
small way, to the use of ever-advancing technology in 
medicine.5p6 However, radiofrequency ablation con- 
trasts with this general trend in that it represents a new 
application of an old technology. The technology has 
been used for several years, for example to treat 
patients with trigeminal neuralgia, and it’s recent appli- 
cation to patients with cardiac arrhythmias has been 
relatively inexpensive. A comparison with coronary an- 
gioplasty is also pertinent. Initial experience with radio- 
frequency ablation suggests that repeat procedures are 
required less frequently than is the case with coronary 
angioplasty and that the initial treatment is usually cu- 
rative rather than palliative.2 This feature serves to re- 
duce medical care costs for patients undergoing radio- 
frequency ablation. 
Comparison with previous studies: In a recent 
study,7 the costs of catheter-mediated direct-current 
shock ablation and surgical ablation in the Wolff-Par- 
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kinson-White syndrome were compared. In that study,7 
the mean total cost per patient, expressed in 1988 dollar 
values, was $14,116 f $4,493 for catheter ablation 
compared to $34,175 f $5,434 for surgical ablation (p 
<O.OOOl). The mean duration of hospitalization was 6 
f 2 days in the group treated with shock ablation com- 
pared with 8 f 4 days in the group treated surgically 
(difference not significant). Direct-current shock abla- 
tion also had a significant indirect economic advantage 
as a result of rapid return to work. The present results 
demonstrate that radiofrequency ablation maintains the 
cost containment associated with direct-current shock 
ablation7 and abbreviates still further the period of hos- 
pitalization for patients undergoing definitive therapy. 
It also permits rapid return to work with beneficial in- 
direct economic effects. 
Comparison of the cost of radiofrequency ablation 
and drug therapy: For the purposes of comparison, we 
examined the cost of treatment with a representative 
antiarrhythmic drug, propafenone, in a hypothetical pa- 
tient with an accessory pathway and recurrent supra- 
ventricular tachycardia. In the case of a dose of 225 mg 
three times daily and a 3-month prescription, refilled 4 
times, the annual cost is $1,000; if 1 year’s supply is 
dispensed at once the cost is $985. Thus, the annual 
cost for this drug alone is approximately $1,000 and 
this does not take into consideration the cost of a diag- 
nostic electrophysiologic test and electropharmacologic 
testing, visits to a physician or emergency room, lost 
productivity because of time away from work, the in- 
convenience associated with taking medication 3 times 
per day, and the possible adverse effects and lifestyle 
restrictions. Based on these figures, radiofrequency ab- 
lation would pay for itself in 5 15 years, and any pa- 
tient who required drugs for > 15 years would save 
money with radiofrequency ablation. Thus, over the 
long term, particularly in younger patients, definitive 
therapy with radiofrequency ablation would appear to 
be more economical than pharmacologic therapy. 
Use of radiofrequency ablation in patients unsuit- 
able for surgical ablation: An interesting finding of the 
present study is the significant difference in age and 
duration of symptoms between patients undergoing ra- 
diofrequency and surgical ablation of accessory path- 
ways. Thus, mean age and symptom duration in the 
radiofrequency group was 40 f 16 (range 14 to 74) 
and 21 f 17 years, respectively, compared to 30 f 11 
(range 13 to 60) and 11 f 11 years in the surgical 
group (p <O.Ol and <0.05, respectively). These data 
reflect the fact that with radiofrequency ablation we 
were able to offer a curative procedure to a much 
broader spectrum of patients and to a group of patients 
that would not otherwise have been considered suitable 
candidates for definitive ablation therapy. In addition to 
their older age, patients in the radiofrequency group 
had a much higher prevalence of general medical dis- 
eases. 
Study limitation: A possible limitation of this study 
is that the cost analysis was retrospective and open. 
This feature may have introduced a certain bias against 
surgery. However, a determined effort was made to 
overcome this potential bias as outlined in the Methods 
section. In addition, we repeated the analysis on a sub- 
group of 10 patients with uncomplicated procedures. 
The cost differentials evident in this subgroup analysis 
were essentially the same as those present in the overall 
analysis. Therefore, we feel that the cost data presented 
are a true and accurate estimate of the cost of these 
procedures. 
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